{"id":4299,"date":"2026-11-13T09:00:00","date_gmt":"2026-11-13T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4299"},"modified":"2026-11-14T12:48:16","modified_gmt":"2026-11-14T16:48:16","slug":"bridging-and-disease-status-before-cd19-car-t","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4299","title":{"rendered":"Bridging and Disease Status Before CD19 CAR T"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"393\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_EBMT_GoCART_Therapeutic_Indications-768x393.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4320\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_EBMT_GoCART_Therapeutic_Indications-768x393.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_EBMT_GoCART_Therapeutic_Indications-300x154.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_EBMT_GoCART_Therapeutic_Indications-1024x524.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_EBMT_GoCART_Therapeutic_Indications-1536x786.png 1536w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261113_EBMT_GoCART_Therapeutic_Indications.png 1752w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>EBMT; GoCART (academic consortium)<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Peer-reviewed publication (Bone Marrow Transplantation)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Autologous CD19 CAR T (axi-cel, tisa-cel)<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Commercial CD19 CAR T<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>CD19<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Relapsed or refractory large B-cell lymphoma<\/p>\n<h4>Summary<\/h4>\n<p>An EBMT and GoCART analysis of 1,134 adults receiving commercial CD19 CAR T for relapsed or refractory large B-cell lymphoma found that 79.5% received bridging therapy. The clinically actionable signal is the association between improvement before lymphodepletion and subsequent outcomes, while treatment-selection bias prevents a causal conclusion about bridging.<\/p>\n<p>The peer-reviewed Bone Marrow Transplantation paper was published online November 13. Patients received axi-cel or tisa-cel during 2018\u2013July 2023 at 38 centers. Three-year progression-free survival was 34.3% with bridging and 44.7% without; overall survival was 44.4% and 57.4%. No bridging remained associated with better PFS and OS after measured adjustment. Among bridged patients, three-year PFS was 47.5% for improved disease status, 28.9% for stable disease and 27.7% for worsened disease.<\/p>\n<h4>Deep Analysis<\/h4>\n<p>These are post-infusion observational comparisons. Bridged recipients had more high-risk features at lymphodepletion, including high LDH, bulky disease and poor performance status; residual confounding by disease kinetics and clinician selection is likely. <strong>Interpretation A:<\/strong> successful cytoreduction creates a lower-burden setting for CAR expansion and persistence; the gradient by interval disease response supports this.<\/p>\n<p><strong>Interpretation B:<\/strong> response to bridging is primarily a marker of favorable tumor biology; the absence of random assignment and disparate baseline risk support that view. The analysis does not establish an optimal bridging regimen or justify withholding needed treatment. Cross-product and contemporary practice portability require caution because the cohort includes two products and ends in 2023.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>CD19 CAR T cells are autologous engineered T cells that recognize CD19 on malignant B cells. Axi-cel and tisa-cel are licensed for eligible large B-cell lymphoma settings. Bridging spans the interval after leukapheresis and before lymphodepletion and infusion; its purpose is to control rapidly progressive disease while cells are manufactured.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Signal: interval disease status may be a more informative trial and care-pathway variable than the binary receipt of bridging.<\/li>\n<li>Missing: randomized regimen comparisons, granular toxicity and access effects, modern product mix, and standardized molecular burden.<\/li>\n<li>Upgrade: prospective risk-adjusted validation across products and a predefined cytoreduction strategy.<\/li>\n<li>Downgrade or falsify: disappearance of the disease-status association after rigorous tumor-kinetic adjustment or in a randomized design.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>The result favors measuring disease control at lymphodepletion and designing bridging trials around objective response, not treating the crude bridged-versus-unbridged survival difference as a treatment effect.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 4 of 5. Signal Direction: mixed. Confidence in Facts: high for reported cohort and estimates. Confidence in Interpretation: moderate because confounding limits causality.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>An EBMT and GoCART analysis of 1,134 adults receiving commercial CD19 CAR T for relapsed or refractory large B-cell lymphoma found that 79.5% received bridging therapy. The clinically actionable signal is the association between&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4320,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[1481,1479,1480],"class_list":["post-4299","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-therapeutic-indication","tag-cd19-car-t","tag-ebmt","tag-gocart"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4299","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4299"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4299\/revisions"}],"predecessor-version":[{"id":4324,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4299\/revisions\/4324"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4320"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4299"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4299"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4299"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}